2026-01-29 - Analysis Report
**Company Overview:**
Amgen is a biotechnology company that discovers, develops, manufactures, and delivers innovative human therapeutics.

**Comparative Return Rate Analysis:**

* Review Stock (AMGN): **94.57%** cumulative return
* Comparison Stock (VOO, S&P 500): **128.51%** cumulative return
* Divergence (max 27.50, min -68.20, current -33.90): **-33.90**
* Relative divergence: **35.80%**

**Financial Performance Analysis:**

|   | AMGN          | S&P 500 (VOO) |
|-----|---------------|---------------|
| Ticker | Company Name | Cumulative Return |
|---------------|---------------|---------------------|
| AMGN          | Amgen      | 94.57%          |
| VOO           | S&P 500    | 128.51%          |

**Degree of Divergence:** -33.90 (current value)

**Alpha, Beta Analysis:**

|   | 2016-2018 | 2017-2019 | 2018-2020 | 2019-2021 | 2020-2022 | 2021-2023 | 2022-2024 | 2023-2025 |
|-----|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| CAGR | 20.00%    | 45.00%    | 18.00%    | 15.00%    | 18.00%    | 21.00%    | 15.00%    | 38.00%    |
| MDD  | 16.10%    | 12.10%    | 21.80%    | 21.80%    | 19.40%    | 20.60%    | 21.20%    | 21.30%    |
| Alpha | 11.00%    | 20.00%    | -6.00%    | -49.00%   | 13.00%    | 3.00%     | -15.00%   | -38.00%   |
| Beta | 1.10      | 0.90      | 0.80      | 0.80      | 0.60      | 0.40      | 0.40      | 0.50      |
| Cap (B) | 102.20    | 126.50    | 120.70    | 118.10    | 137.80    | 151.20    | 136.80    | 171.80    |

**Recent Price Fluctuations:**

* Close: $351.32
* 5-day SMA: $347.29
* 20-day SMA: $333.43
* 60-day SMA: $329.71

**RSI, PPO Index Indicators, and Delta_Previous_Relative_Divergence:**

* Market Risk Indicator (MRI): 0.70
* RSI: 67.49
* PPO: 0.69
* Hybrid Signal: Buy (Cash 0%)
* Risk Level: Medium (MRI 0.70)
* Recent (20 days) relative divergence change: 5.60 (+): improving
* 7-day Rank change: -31 (-): rank down
* 7-day Dynamic Expected Return change: -25.90 (-): worsening
* Expected Return (%): -27.20%

**News & Significant Events:**

1. **Truist Financial Corp Reduces Stock Position in Amgen Inc. $AMGN** (MarketBeat)
2. **Amgen Set to Report Q4 Earnings: What Investors Should Know** (TradingView)
3. **Amgen (AMGN) Laps the Stock Market: Here's Why** (Yahoo Finance)
4. **Earnings Preview: Qiagen (QGEN) Q4 Earnings Expected to Decline** (Finviz)
5. **Should You Stay Invested in J&J Stock After Q4 Beat & Solid Guidance?** (The Globe and Mail)
6. **Is It Time To Reassess Amgen (AMGN) After Strong Multi Year Share Price Gains** (Simply Wall St)

**Analyst Opinions:**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.41 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): 331.96 / 425.00 / 180.00

**Recent Earnings Analysis:**

|   | Date | EPS | Revenue |
|-----|------|-----|---------|
| 2025-11-05 | 5.98 | $9.56B |
| 2025-08-06 | 2.66 | $9.18B |
| 2025-05-02 | 3.22 | $8.15B |
| 2024-10-31 | 5.27 | $8.50B |
| 2025-11-05 | 5.27 | $8.50B |

**Revenue and Profitability Analysis:**

|   | Quarter | Revenue | Profit Margin |
|-----|---------|---------|---------------|
| 2025-09-30 | $9.56B | 67.75% |
| 2025-06-30 | $9.18B | 67.20% |
| 2025-03-31 | $8.15B | 63.58% |
| 2024-12-31 | $9.09B | 65.75% |
| 2024-09-30 | $8.50B | 61.07% |

**Capital and Profitability Analysis:**

|   | Quarter | Equity | ROE |
|-----|---------|--------|-----|
| 2025-09-30 | $9.62B | 33.43% |
| 2025-06-30 | $7.43B | 19.28% |
| 2025-03-31 | $6.21B | 27.87% |
| 2024-12-31 | $5.88B | 10.67% |
| 2024-09-30 | $7.53B | 37.60% |

**Comprehensive Analysis (Summary of previous items):**

* **Company Overview:** Amgen is a biotechnology company that discovers, develops, manufactures, and delivers innovative human therapeutics.
* **Financial Performance Analysis:**
	+ Cumulative return of review stock (AMGN): 94.57%
	+ Cumulative return of comparison stock (VOO, S&P 500): 128.51%
	+ Degree of divergence: -33.90 (current value)
* **Alpha, Beta Analysis:**
	+ CAGR values range from 15.00% to 45.00%
	+ Alpha and Beta values are mostly positive, with some negative values indicating potential risks
* **RSI, PPO Index Indicators, and Delta_Previous_Relative_Divergence:**
	+ Market Risk Indicator (MRI): 0.70 (Medium risk level)
	+ RSI and PPO values are moderate, indicating possible buy signals
* **News & Significant Events:** Recent news and events suggest Amgen's strong quarterly performance and possible future growth.
* **Analyst Opinions:**
	+ Analyst consensus: Buy
	+ Mean (1=StrongBuy~5=Sell): 2.41 (~Buy)
	+ Opinions: 27
	+ Target Price (avg/high/low): 331.96 / 425.00 / 180.00
* **Recent Earnings Analysis:**
	+ EPS and revenue values range from $2.66 to $9.56B
	+ Revenue growth continues to increase over the past few quarters
* **Revenue and Profitability Analysis:**
	+ Profit margin values range from 61.07% to 67.75%
	+ Revenue growth and profit margin consistency suggest a stable company performance
* **Capital and Profitability Analysis:**
	+ Equity and ROE values range from $5.88B to $9.62B
	+ ROE values are mostly positive, indicating a stable and profitable company performance

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.